Andarix Pharmaceuticals CEO Christopher P. Adams will participate in a panel discussion on "AI in Clinical Trials: Innovation, Challenges, and Execution in Modern Trial Development" at the 26th BioPharma Clinical Trials Nexus. Adams will join senior leaders from AstraZeneca, Ultragenyx, and Bristol Myers Squibb to explore how artificial intelligence is reshaping clinical trial design and execution. The panel takes place Day 1, 11:55 AM – 12:50 PM.
Boston, MA, United States, 7th May 2026 - Andarix Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation targeted radiopharmaceuticals for oncology, today announced that Chief Executive Officer Christopher P. Adams will serve as a panelist at the 26th BioPharma Clinical Trials Nexus conference. Mr. Adams will participate in the panel discussion titled “AI in Clinical Trials: Innovation, Challenges, and Execution in Modern Trial Development,” scheduled for Day 1 of the conference from 11:55 AM to 12:50 PM.
The panel will bring together senior leaders from across the biopharmaceutical industry to examine the growing role of artificial intelligence in clinical trial design, data management, and operational execution. Topics are expected to include practical applications of AI in trial development, the regulatory and ethical considerations surrounding its adoption, and strategies for integrating AI-driven tools into existing clinical infrastructure.
Mr. Adams will join fellow panelists from AstraZeneca, Ultragenyx Pharmaceutical, Bristol Myers Squibb, and Inferential Data LLC, moderated by Dr. Divesh Kumar, Global Head of Biowelness Lifescience Pvt. Ltd.
“AI is fundamentally reshaping how clinical trials are designed and executed, and I look forward to sharing Andarix’s perspective on how emerging technologies can accelerate development timelines while maintaining rigorous scientific standards,” said Christopher P. Adams, CEO of Andarix Pharmaceuticals. “For a clinical-stage company like Andarix, the ability to leverage data-driven tools to optimize patient selection and trial efficiency is directly relevant to advancing our pipeline toward meaningful patient outcomes.”
The 26th BioPharma Clinical Trials Nexus is a premier industry conference convening clinical operations professionals, biotech and pharma executives, CRO leaders, and patient advocacy representatives across a two-day program. The conference features panel discussions, roundtable sessions, and networking opportunities focused on the evolving landscape of clinical trial design, regulatory compliance, patient engagement, and technology innovation.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company’s products have progressed through early clinical development. The Andarix technology is based on a proprietary somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and other cancers.
Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung, neuroendocrine, and pancreatic tumors. To learn more about Andarix, please visit www.andarix.com.
Media Contact
Organization: Andarix Pharmaceuticals
Contact Person: Chris Adams
Website: https://andarix.com
Email: Send Email
Contact Number: +16179579858
Address:1660 Soldiers Field Rd
City: Boston
State: MA
Country:United States
Release id:44771
The post Andarix Pharmaceuticals CEO to Participate in Panel on AI in Clinical Trials at 26th BioPharma Clinical Trials Nexus appeared first on King Newswire. This content is provided by a third-party source.. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section above.
Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.
